NASDAQ:PGNX - Progenics Pharmaceuticals Stock Price, Price Target & More

Get Started

$7.52 +0.01 (+0.13 %)

(As of 05/27/2018 10:04 AM ET)

Previous Close$7.52

Today's Range$7.42 - $7.56

52-Week Range$4.60 - $8.63

Volume493,727 shs

Average Volume1.07 million shs

Market Capitalization$554.37 million

P/E Ratio-8.36

Dividend YieldN/A

Beta2.52

About Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

Receive PGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:PGNX

CUSIP74318710

Webwww.progenics.com

Phone646-975-2500

Debt

Debt-to-Equity Ratio0.74

Current Ratio6.44

Quick Ratio6.44

Price-To-Earnings

Trailing P/E Ratio-8.36

Forward P/E Ratio-13.67

P/E GrowthN/A

Sales & Book Value

Annual Sales$11.70 million

Price / Sales47.38

Cash FlowN/A

Price / CashN/A

Book Value$0.82 per share

Price / Book9.17

Profitability

EPS (Most Recent Fiscal Year)($0.90)

Net Income$-51,010,000.00

Net Margins-383.39%

Return on Equity-92.43%

Return on Assets-39.20%

Miscellaneous

Employees64

Outstanding Shares73,720,000

Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) released its earnings results on Wednesday, May, 9th. The biotechnology company reported ($0.19) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.04. The biotechnology company earned $3.19 million during the quarter, compared to analysts' expectations of $4.10 million. Progenics Pharmaceuticals had a negative return on equity of 92.43% and a negative net margin of 383.39%. View Progenics Pharmaceuticals' Earnings History.

When is Progenics Pharmaceuticals' next earnings date?

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Progenics Pharmaceuticals.

What price target have analysts set for PGNX?

4 brokerages have issued twelve-month price objectives for Progenics Pharmaceuticals' shares. Their forecasts range from $12.00 to $15.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $13.75 in the next twelve months. View Analyst Ratings for Progenics Pharmaceuticals.

What are Wall Street analysts saying about Progenics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:

1. Cantor Fitzgerald analysts commented, ". We maintain an Overweight rating and 12-month PT of $15 on the shares of PGNX. Although we like the rare disease opportunity for AZEDRA (PDUFA 7/30), we also like the PSMA-targeted pipeline for prostate cancer. Moreover, what we have come to appreciate in the PGNX story is the optionality of the pipeline, which extends to the potential for out-licensing, financing and clinical development." (5/20/2018)
2. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (5/11/2018)

Who are some of Progenics Pharmaceuticals' key competitors?

Some companies that are related to Progenics Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Xencor (XNCR), Corcept Therapeutics (CORT), Insmed (INSM), Intercept Pharmaceuticals (ICPT), OPKO Health (OPK), Akcea Therapeutics (AKCA), Puma Biotechnology (PBYI), Spectrum Pharmaceuticals (SPPI), Aimmune Therapeutics (AIMT), Enanta Pharmaceuticals (ENTA), Prestige Brands (PBH), AnaptysBio (ANAB), Phibro Animal Health (PAHC) and Akorn (AKRX).

Who are Progenics Pharmaceuticals' key executives?

Progenics Pharmaceuticals' management team includes the folowing people:

Mr. Mark R. Baker, CEO & Director (Age 63)
Mr. Patrick Fabbio, Sr. VP, CFO & Principal Accounting Officer (Age 50)
Dr. Vivien Wong, Exec. VP of Devel. (Age 61)
Mr. Jeffrey D. Summer, Sr. VP of Digital Technology (Age 58)
Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 45)

Has Progenics Pharmaceuticals been receiving favorable news coverage?

Press coverage about PGNX stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Progenics Pharmaceuticals earned a news impact score of 0.16 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 45.16 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Progenics Pharmaceuticals' major shareholders?

Progenics Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.55%), Eagle Asset Management Inc. (6.06%), Carillon Tower Advisers Inc. (5.36%), Pinnacle Associates Ltd. (2.85%), Summit Trail Advisors LLC (0.55%) and Schwab Charles Investment Management Inc. (0.49%). View Institutional Ownership Trends for Progenics Pharmaceuticals.

Which major investors are selling Progenics Pharmaceuticals stock?

PGNX stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Wells Fargo & Company MN, American International Group Inc., BKS Advisors LLC, Teacher Retirement System of Texas and BlackRock Inc.. View Insider Buying and Selling for Progenics Pharmaceuticals.

Which major investors are buying Progenics Pharmaceuticals stock?

PGNX stock was acquired by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Eagle Asset Management Inc., Carillon Tower Advisers Inc., JPMorgan Chase & Co., UBS Group AG, A.R.T. Advisors LLC, Bayesian Capital Management LP and Jane Street Group LLC. View Insider Buying and Selling for Progenics Pharmaceuticals.

How do I buy shares of Progenics Pharmaceuticals?

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Progenics Pharmaceuticals' stock price today?

One share of PGNX stock can currently be purchased for approximately $7.52.

How big of a company is Progenics Pharmaceuticals?

Progenics Pharmaceuticals has a market capitalization of $554.37 million and generates $11.70 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Progenics Pharmaceuticals employs 64 workers across the globe.

How can I contact Progenics Pharmaceuticals?

Progenics Pharmaceuticals' mailing address is 285 FULTON STREET 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]

MarketBeat Community Rating for Progenics Pharmaceuticals (PGNX)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		240 (Vote Outperform)
Underperform Votes:		186 (Vote Underperform)
Total Votes:		426

MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Progenics Pharmaceuticals (NASDAQ:PGNX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for Progenics Pharmaceuticals in the last 12 months. Their average twelve-month price target is $13.75, suggesting that the stock has a possible upside of 82.85%. The high price target for PGNX is $15.00 and the low price target for PGNX is $12.00. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.25	3.25	3.25	3.20
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 1 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 1 Strong Buy Rating(s)
Consensus Price Target:	$13.75	$13.75	$13.75	$13.20
Price Target Upside:	82.85% upside	64.47% upside	123.58% upside	113.25% upside

Progenics Pharmaceuticals (NASDAQ:PGNX) Consensus Price Target History

Price Target History for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ:PGNX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/20/2018	Cantor Fitzgerald	Set Price Target	Buy	$15.00	Low
9/1/2017	Needham & Company LLC	Reiterated Rating	Strong-Buy	$14.00	Medium
8/22/2017	Aegis	Reiterated Rating	Buy	$14.00	Low
6/8/2017	Jefferies Group	Reiterated Rating	Buy	$12.00	High
11/30/2016	BTIG Research	Boost Price Target	Buy	$9.00 ➝ $11.00	N/A
10/4/2016	Brean Capital	Initiated Coverage	Buy	$11.00	N/A

(Data available from 5/27/2016 forward)

Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings History and Estimates Chart

Earnings by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings Estimates

2018 EPS Consensus Estimate: ($0.66)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.23)	($0.23)	($0.23)
Q2 2018	1	($0.19)	($0.19)	($0.19)
Q3 2018	1	($0.18)	($0.18)	($0.18)
Q4 2018	1	($0.06)	($0.06)	($0.06)

Progenics Pharmaceuticals (NASDAQ PGNX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/7/2018		($0.19)					N/A
5/9/2018	Q1 2018	($0.23)	($0.19)	$4.10 million	$3.19 million	View	N/A
3/8/2018	Q4 2017	($0.21)	($0.21)	$3.18 million	$3.90 million	View	N/A
11/2/2017	Q3 2017	($0.24)	($0.22)	$3.58 million	$2.70 million	View	N/A
8/9/2017	Q2 2017	($0.20)	($0.24)	$3.34 million	$2.77 million	View	Listen
5/4/2017	Q1 2017	($0.16)	($0.23)	$4.50 million	$2.40 million	View	Listen
3/9/2017	Q4 2016	($0.20)	($0.10)	$4.43 million	$4.65 million	View	Listen
11/7/2016	Q316	$0.55	$0.52	$52.90 million	$53.90 million	View	Listen
8/4/2016	Q216	($0.13)	($0.08)	$6.33 million	$8.50 million	View	N/A
5/5/2016	Q116	($0.13)	($0.18)	$3.27 million	$2.50 million	View	Listen
3/11/2016	Q415	($0.14)	($0.10)	$2.25 million	$5.10 million	View	Listen
11/9/2015	Q315	($0.13)	($0.14)	$2.35 million	$1.40 million	View	Listen
8/6/2015	Q215	($0.15)	($0.17)	$1.63 million	$1.90 million	View	Listen
5/6/2015	Q115	($0.16)	($0.15)	$1.30 million	$0.25 million	View	N/A
3/16/2015	Q414	($0.13)	($0.18)	$2.87 million	($0.57) million	View	N/A
11/7/2014	Q314	($0.16)	$0.51	$2.50 million	$41.66 million	View	N/A
8/8/2014	Q214	($0.14)	($0.17)	$2.83 million	$1.50 million	View	Listen
5/9/2014	Q114	($0.15)	($0.15)	$2.88 million	$1.80 million	View	N/A
3/13/2014	Q4	($0.19)	($0.14)	$1.48 million	$3.00 million	View	Listen
3/3/2014	Q4 2013	($0.19)	($0.14)	$1.74 million	$2.97 million	View	N/A
11/11/2013	Q313	($0.22)	($0.17)	$2.00 million	$0.90 million	View	N/A
8/9/2013	Q2 2013	($0.24)	($0.24)	$1.86 million	$1.80 million	View	N/A
5/10/2013	Q1 2013	($0.19)	($0.22)	$1.71 million	$2.23 million	View	N/A
3/15/2013	Q4 2012	($0.31)	($0.01)	$1.16 million	$8.87 million	View	N/A
11/8/2012	Q312	($0.30)	($0.33)	$2.52 million	$1.10 million	View	N/A
8/9/2012		($0.32)	($0.32)			View	N/A
5/8/2012		($0.33)	($0.39)			View	N/A
3/15/2012	Q4 2011	($0.25)	($0.32)			View	N/A
11/9/2011		($0.33)	($0.34)			View	N/A
8/9/2011		($0.25)	$1.64			View	N/A
5/10/2011		($0.51)	($0.69)			View	N/A
3/15/2011		($0.57)	($0.57)			View	N/A
11/8/2010	Q3 2010	($0.56)	($0.52)			View	N/A
8/9/2010	Q2 2010	($0.54)	($0.47)			View	N/A
5/10/2010	Q1 2010	($0.41)	($0.58)			View	N/A
3/15/2010	Q4 2009	($0.14)	($0.02)			View	N/A
11/9/2009	Q3 2009	($0.44)	($0.41)			View	N/A
8/6/2009	Q2 2009	($0.50)	($0.50)			View	N/A
5/11/2009	Q1 2009	($0.27)	($0.06)			View	N/A
3/13/2009	Q4 2008	($0.30)	($0.49)			View	N/A
11/10/2008	Q3 2008	($0.28)	($0.41)			View	N/A
8/8/2008	Q2 2008	$0.01	($0.08)			View	N/A
5/9/2008	Q1 2008	($0.41)	($0.52)			View	N/A
3/17/2008	Q4 2007	($0.46)	($0.53)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Progenics Pharmaceuticals (NASDAQ:PGNX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.63%
Institutional Ownership Percentage: 86.46%

Insider Trading History for Progenics Pharmaceuticals (NASDAQ:PGNX)

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
2/15/2017	Healthcare Master Fun Broadfin	Major Shareholder	Sell	602,600	$9.66	$5,821,116.00
2/9/2017	Healthcare Master Fun Broadfin	Major Shareholder	Sell	351,300	$9.71	$3,411,123.00
6/11/2015	Robert J Israel	EVP	Sell	2,000	$6.83	$13,660.00
3/13/2015	Robert J Israel	EVP	Sell	3,000	$7.00	$21,000.00
3/11/2015	Robert J Israel	EVP	Sell	2,000	$6.83	$13,660.00
3/3/2015	Robert J Israel	EVP	Sell	5,000	$6.49	$32,450.00
1/12/2015	Robert J Israel	EVP	Sell	2,000	$7.06	$14,120.00
12/11/2014	Robert J Israel	EVP	Sell	3,000	$7.07	$21,210.00
11/21/2014	Robert J Israel	EVP	Sell	9,000	$7.00	$63,000.00
11/13/2014	Robert J Israel	EVP	Sell	10,000	$6.83	$68,300.00
11/11/2014	Robert J Israel	EVP	Sell	5,000	$6.53	$32,650.00
7/21/2014	Healthcare Master Fun Broadfin	Major Shareholder	Buy	1,625,436	$4.60	$7,477,005.60
7/18/2014	Healthcare Master Fun Broadfin	Major Shareholder	Buy	388,200	$4.73	$1,836,186.00
7/17/2014	Healthcare Master Fun Broadfin	Major Shareholder	Buy	436,884	$4.48	$1,957,240.32
7/16/2014	Healthcare Master Fun Broadfin	Major Shareholder	Buy	411,693	$4.48	$1,844,384.64
7/18/2013	Robert J Israel	VP	Sell	5,000	$6.33	$31,650.00
2/27/2013	Mark Robert Baker	CEO	Buy	1,262	$2.72	$3,432.64
1/22/2013	Mark Robert Baker	CEO	Buy	1,215	$2.82	$3,426.30
12/26/2012	Mark Robert Baker	CEO	Buy	1,142	$3.01	$3,437.42
11/28/2012	Mark Robert Baker	CEO	Buy	1,607	$2.13	$3,422.91
11/19/2012	Mark Robert Baker	CEO	Buy	11,800	$1.96	$23,128.00
11/16/2012	Mark Robert Baker	CEO	Buy	49,793	$1.82	$90,623.26
11/15/2012	Mark Robert Baker	CEO	Buy	48,833	$1.69	$82,527.77
10/24/2012	Mark Robert Baker	CEO	Buy	1,162	$2.96	$3,439.52
9/26/2012	Mark Robert Baker	CEO	Buy	1,036	$3.32	$3,439.52

(Data available from 1/1/2013 forward)

Progenics Pharmaceuticals (NASDAQ PGNX) News Headlines

Source:

Date	Headline
	Traders Purchase High Volume of Call Options on Progenics Pharmaceuticals (PGNX) www.americanbankingnews.com - May 25 at 6:44 AM
	Progenics Pharmaceuticals, Inc. (PGNX) to Post FY2018 Earnings of ($0.63) Per Share, Cantor Fitzgerald Forecasts www.americanbankingnews.com - May 24 at 8:22 AM
	Progenics' aBSI shows prognostic value in late-stage study seekingalpha.com - May 22 at 4:42 PM
	Progenics Announces JAMA Oncology Publication Highlighting Company’s Imaging Analysis Platform finance.yahoo.com - May 22 at 8:56 AM
	Progenics Pharmaceuticals: Elucidating The Upcoming Regulatory Binary For Azedra seekingalpha.com - May 21 at 9:19 AM
	Progenics Pharmaceuticals (PGNX) Earns Buy Rating from Cantor Fitzgerald www.americanbankingnews.com - May 20 at 9:30 PM
	Global Prostate Cancer Therapeutics Strategic Business Report Analysis 2015-2018 Forecast to 2022 www.prnewswire.com - May 18 at 4:43 PM
	Progenics Pharmaceuticals (PGNX) Given Consensus Rating of "Buy" by Brokerages www.americanbankingnews.com - May 14 at 5:58 AM
	Q2 2018 EPS Estimates for Progenics Pharmaceuticals (PGNX) Increased by Analyst www.americanbankingnews.com - May 14 at 1:58 AM
	BRIEF-Progenics Pharma, Valeant, Others & Par Sterile Products, Par Pharma Entered Settlement Agreement Relating ... www.reuters.com - May 13 at 9:37 AM
	Progenics Pharmaceuticals (PGNX) Raised to "Hold" at Zacks Investment Research www.americanbankingnews.com - May 11 at 12:49 PM
	Progenics Pharmaceuticals (PGNX) Forecasted to Post FY2021 Earnings of $0.63 Per Share www.americanbankingnews.com - May 11 at 11:47 AM
	Progenics Earnings: Get Ready For A Massive Move seekingalpha.com - May 10 at 9:28 AM
	Edited Transcript of PGNX earnings conference call or presentation 9-May-18 12:30pm GMT finance.yahoo.com - May 10 at 9:28 AM
	Progenics Pharmaceuticals Sees Unusually Large Options Volume (PGNX) www.americanbankingnews.com - May 10 at 7:40 AM
	Progenics Pharmaceuticals' (PGNX) CEO Mark Baker on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 9 at 4:42 PM
	Progenics Pharmaceuticals (PGNX) Given a $15.00 Price Target by Cantor Fitzgerald Analysts www.americanbankingnews.com - May 9 at 3:17 PM
	Progenics Pharmaceuticals (PGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS www.americanbankingnews.com - May 9 at 2:25 PM
	Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update globenewswire.com - May 9 at 9:15 AM
	Progenics Pharmaceuticals beats by $0.02, misses on revenue seekingalpha.com - May 9 at 9:15 AM
	Progenics revenues up 39%; net loss improves in Q1 seekingalpha.com - May 9 at 9:15 AM
	Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update finance.yahoo.com - May 9 at 9:15 AM
	Progenics: 1Q Earnings Snapshot finance.yahoo.com - May 9 at 9:15 AM
	Noteworthy Tuesday Option Activity: BA, PGNX, AMBA www.nasdaq.com - May 8 at 4:43 PM
	New Analyst Coverage Puts Spotlight on These 4 Stocks finance.yahoo.com - May 7 at 4:46 PM
	Progenics Pharmaceuticals (PGNX) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - May 7 at 11:58 AM
	Summary Judgment Granted Upholding the Validity of Formulation Patent Protecting RELISTOR® Injection feeds.benzinga.com - May 2 at 9:45 PM
	The No BS Report, Week 11: Rising Tides And Sinking Ships? seekingalpha.com - May 1 at 9:07 AM
	Research Report Identifies Cracker Barrel Old Country Store, Enova International, Natera, Inovalon, UMH Properties ... globenewswire.com - May 1 at 9:07 AM
	BidaskClub Lowers Progenics Pharmaceuticals (PGNX) to Hold www.americanbankingnews.com - May 1 at 8:12 AM
	Progenics Pharmaceuticals Sets First Quarter 2018 Financial Results Call for May 9 finance.yahoo.com - April 26 at 9:11 AM
	Progenics Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting finance.yahoo.com - April 26 at 9:11 AM
	Progenics Pharmaceuticals (PGNX) to Release Earnings on Wednesday www.americanbankingnews.com - April 25 at 7:33 AM
	Progenics Pharmaceuticals (PGNX) Downgraded by BidaskClub www.americanbankingnews.com - April 21 at 7:24 AM
	Progenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 19 at 12:49 PM
	Progenics Pharmaceuticals, Inc. (PGNX) Receives Consensus Recommendation of "Buy" from Brokerages www.americanbankingnews.com - April 19 at 5:56 AM
	Cantor Fitzgerald Begins Coverage on Progenics Pharmaceuticals (PGNX) www.americanbankingnews.com - April 18 at 8:34 PM
	Progenics Pharmaceuticals (PGNX) PT Set at $15.00 by Cantor Fitzgerald www.americanbankingnews.com - April 11 at 7:19 PM
	Progenics Talks Commercialization, Pipeline, And Milestones seekingalpha.com - April 10 at 9:29 AM
	Progenics Pharmaceuticals' (PGNX) Buy Rating Reaffirmed at Aegis www.americanbankingnews.com - April 9 at 10:55 PM
	Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research to "Sell" www.americanbankingnews.com - April 7 at 7:02 AM
	Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 6 at 6:29 PM
	Equities Analysts Set Expectations for Progenics Pharmaceuticals, Inc.'s FY2018 Earnings (PGNX) www.americanbankingnews.com - April 6 at 7:24 AM
	Progenics Pharmaceuticals (PGNX) Downgraded to "Sell" at Zacks Investment Research www.americanbankingnews.com - April 1 at 11:52 AM
	Progenics Pharmaceuticals (PGNX) Given a $15.00 Price Target at Cantor Fitzgerald www.americanbankingnews.com - March 31 at 10:54 AM
	Progenics Pharmaceuticals (PGNX) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - March 30 at 6:15 PM
	Progenics Pharmaceuticals (PGNX) Downgraded to "Sell" at ValuEngine www.americanbankingnews.com - March 28 at 12:24 PM
	Progenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from Brokerages www.americanbankingnews.com - March 25 at 5:32 AM
	3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News seekingalpha.com - March 24 at 5:12 PM
	Progenics Pharmaceuticals (PGNX) Rating Increased to Buy at BidaskClub www.americanbankingnews.com - March 24 at 3:52 PM

Progenics Pharmaceuticals (NASDAQ:PGNX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Progenics Pharmaceuticals (NASDAQ:PGNX) Income Statement, Balance Sheet and Cash Flow Statement

Progenics Pharmaceuticals (NASDAQ PGNX) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff